Procainamide
Participation, are such as to facilitate the maximum level of Irish participation in the programme. At a national level we have taken up the challenges set under the Lisbon Agenda, with the aim of making the Union the most competitive, knowledge-based economy in the World by 2010. This includes the goal that overall spending on research and development and innovation in the EU should be increased to 3% of GDP by 2010, with two thirds of this spend to come from industry. In August 2004, the interdepartmental group set up to examine the national policy implications of the EU's Lisbon Agenda targets on investment in research and development and to make recommendations on how Ireland should respond, reported with Building Ireland's Knowledge Economy-the Irish Action Plan for promoting investment in research and development to 2010. The action plan took as its starting point the substantial increase in investment by the Government in science, technology and innovation which has resulted in a five-fold increase in investment in the National Development Plan 2000-2006 to .48 billion, compared with ##TEXT##.5 billion over the period 1994-99. It sets the vision that Ireland by 2010 will be internationally renowned for the excellence of its research and be at the forefront in generating and using new knowledge for economic and social progress, within an innovation driven culture. To realise this vision, the analysis undertaken reveals that the following targets must be achieved: business investment in research and development should increase from 7 million in 2001 -- 0.9% GNP -- to .5 billion in 2010 or 1.7% GNP. This would entail a doubling of the number of companies with minimum scale research and development activity and a quadrupling of the number of enterprises performing significant research and development. Research and development performance in the higher education and public sectors should increase from 2 million in 2001 -- 0.4% GNP -- to .1 billion in 2010 or 0.8% GNP. The combined increases in performance in business, higher education and public sector research and development should result in gross expenditure on research and development increasing to 2.5% of GNP by 2010. Consequently, the number of researchers should reach 9.3 per 1, 000 of total employment by 2010, from approximately 5.1 per 1, 000 in 2001. To work towards these ambitious targets, a Government strategic approach is required. The IDC, established as part of the Government decision on co-ordination and governance of STI, provides an appropriate high level and interdepartmental arena to make recommendations to Cabinet on the steps necessary to implement the research and development national action plan.
Last Name 1. 2. 3. Isuprel isoproterenol ; 5. Tegretol Carbamazepine ; 6. Dilantin phenytoin ; 7. Insulin all types ; 8. Decadron dexamethasone ; 9. Valium diazepam ; 10. Versed 11. Sodium Bicarbonate 12. Demerol 13. Phenergan 14. Thorazine 15. Morphine 16. Amiodarone cararone ; 17. Atropine 18. Inocor amrinone ; 19. Diltiazem cardizem ; 20. Dobutamine dobutrex ; 21. Dopamine intropin ; 22. Lidocaine Xylocaine ; 23. Metroprolol lopressor ; 24. Nipride nitroprusside ; 25. Nitroglycerine tridil ; 26. Procainamide pronestyl ; 27. Reteplase recombinant retavase ; 28. Streptokinase 29. TPA slteplase ; 30. Verapamil calan, isoptin, verelan ; 31. AquaMephyton vitamin K ; 32. Inderal propranolol ; 33. Kayexelate 34.Epinephrine adrenalin ; 35. Pitressin vasopressin ; 36. Lasix furosemide ; K. Basic Nursing Care Skill & Knowledge of Patients Needing Or With: 1. Oxygen therapy 2. Oximetry reading 3. Aspiration 4. ET tube 5. Oral airway insertion 6. Internal cardioverter defibrillator L. Participation and or Assisting Physician with Patients that Require: 1. Arterial line insertion 2. Intubation 3. Swaz-Ganz PA catheter insertion 4. Central line insertion.
New-onset atrial fibrillation AF ; occurs frequently in patients after cardiac surgery. The purpose of this study was to review the published trials and to provide clinical practice guidelines for pharmacologic prophylaxis against postoperative AF. Trials of pharmacologic prophylaxis against AF after heart surgery were identified by searching MEDLINE, the Cochrane Controlled Trials Register, and the bibliographies of published reports. Evidence grades and clinical recommendation scores were assigned to each prophylactic drug based on published evidence. Ninety-one trials were identified. The primary study design was a randomized, controlled trial of one drug vs placebo usual care. Pharmacologic therapies that are reviewed include Vaughan-Williams class II agents ie, -receptor antagonists ; [29 trials; 2, 901 patients], Vaughan-Williams class III agents ie, sotalol and amiodarone ; [18 trials; 2, 978 patients], Vaughan-Williams class IV agents ie, verapamil and diltiazem ; [5 trials; 601 patients], and Vaughan-Williams class I agents ie, quinidine and procainamide ; [3 trials; 246 patients], as well as digitalis 10 trials; 1, 401 patients ; , magnesium 14 trials; 1, 853 patients ; , dexamethasone 1 trial; 216 patients ; , glucose-insulinpotassium 3 trials; 102 patients ; , insulin 1 trial; 501 patients ; , triiodothyronine 2 trials; 301 patients ; , and aniline 1 trial; 32 patients ; . A consistent finding in this review is that antiarrhythmic drugs with -adrenergic receptor-blocking effects ie, class II beta-blockers, sotalol, and amiodarone ; demonstrated successful prophylaxis. Furthermore, those therapies that did not inhibit -receptors generally failed to demonstrate a decreased incidence in postoperative AF. While sotalol and amiodarone have been shown in some studies to be effective, their safety and the incremental prophylactic advantage in comparison with beta-blockers has not been conclusively demonstrated. On the basis of evidence that has been reviewed and graded for quality, it is recommended that strong consideration should be given to the prophylactic administration of Vaughan-Williams class II beta-blocking drugs as a means of lowering the incidence of new-onset post-cardiac surgery AF. CHEST 2005; 128: 39S.
Graduate Center for Toxicology R.A.B. ; , and College of Pharmacy, Division of Pharmaceutical Sciences A.M.W., S.M.P., G.H., R.A.B. ; , University of Kentucky, Lexington, Kentucky Received October 30, 1998; accepted March 12, 1999.
Katsura, Toshiya, Hiroshi Mizuuchi, Yukiya Hashimoto, and Ken-ichi Inui. Transport of procainamide via H tertiary amine antiport system in rabbit intestinal brushborder membrane. J Physiol Gastrointest Liver Physiol 279: G799G805, 2000.--Transport characteristics of procainamide in the brush-border membrane isolated from rabbit small intestine were studied by a rapid-filtration technique. Procainamide uptake by brush-border membrane vesicles was stimulated by an outward H gradient pHin 6.0, pHout 7.5 ; against a concentration gradient overshoot phenomenon ; , and this stimulation was reduced when the H gradient was subjected to rapid dissipation by the presence of a protonophore, FCCP. An outward H gradientdependent procainamide uptake was not caused by H diffusion potential. The initial uptake of procainamide was inhibited by other tertiary amines with N-dimethyl or Ndiethyl moieties in their structures, such as triethylamine, dimethylaminoethyl chloride, and diphenhydramine, but not by tetraethylammonium and thiamine. Furthermore, procainamide uptake was stimulated by preloading the vesicles with these tertiary amines trans-stimulation effect ; , indicating the existence of a specific transport system for tertiary amines. These findings indicate that procainamide transport in the intestinal brush-border membrane is mediated by the H tertiary amine antiport system that recognizes N-dimethyl or N-diethyl moieties in the structures of tertiary amines. organic cation; intestinal absorption; intestinal secretion; antiporter.
Unless otherwise indicated, values are given as percentage and 95% confidence interval. The number of subjects receiving placebo. This trial reports the sum of all patients with symptoms at any time during investigation. The 2552 participants mean age, 47.6 years [range, 16-99 years]; female sex, 52.7% ; were selected as representative of the German population. All symptoms were rated for the last 7 days on a 5-point Likert scale 1, not at all; 2, a little; 3, medium; 4, severe; 5, very severe ; . Publication in preparation; data available from 1 of us W.R and procaine.
The aim of the present study was to assess acute lipolytic actions of GH and cortisol at the whole body level and in subcutaneous adipose tissue and skeletal muscle, since these hormones are cosecreted during fasting 3, 33 ; , exercise 11, 12, 26, ; , and other kinds of perceived stress 43 ; . In line with our previous studies involving GH and cortisol, we observed an increase in the circulating lipolytic parameters FFA and glycerol upon stimulation. Interstitial adipose tissue lipolysis, although technical difficulties prevailed, also showed similar results to those found previously. The novelty of this study clearly lies in the additive effects of the two hormones.
Dopamine 400mg 250ml pre-mixed 9 ; heparin 10, 000 units ml; 1 ml vial 10 ; inderal propranolol ; 1mg ml; 1 ml ampule 11 ; isuprel isoproterenol ; 1mg 5ml; 1: ampule 12 ; lanoxin digoxin ; 0.5 mg 2ml ampule 13 ; lasix furosemide ; 40 mg 4ml vial 14 ; lidocaine Abboject 2%; 100mg 5ml ; lidocaine 2 grams 500ml pre-mixed 16 ; magnesium sulfate 50%; 20ml vial 1g 2ml ; 17 ; narcan naloxone ; 0.4mg ml; 1ml ampule 18 ; pronestyl procainamide ; 100mg ml; 10ml vial 19 ; sodium bicarbonate Abboject 50mEq 50ml 20 ; solu-medrol methylprednisolone ; 125mg 2ml vial 21 ; verapamil syringe 5mg 2ml 22 ; romazicon 5ml or 10 ml 0.1mg ml ; The above dosage levels may be adjusted, depending on ages of the patient population. b. Suction devices, endotracheal tubes, laryngoscopes, etc. c. Positive pressure ventilation device e.g., Ambu ; plus oxygen supply. d. Double tourniquet for the Bier Block procedure. e. Monitors for blood pressure EKG Oxygen saturation and portable approved defibrillator. f. Emergency intubation equipment. g. Adequate operating room lighting. h. Emergency power source able to produce adequate power to run required equipment for a minimum of two 2 ; hours, which would require generator on site. i. Appropriate sterilization equipment. j. IV solution and IV equipment and procarbazine.
Order procainamide online
Assessment Assess vital signs prior to administration. Do not administer to patient with a current or recent febrile illness; low grade fever 100F ; and mild upper respiratory infection and usually not contraindicated.
ITEM NUMBER 3753 3754 3755 CHARGE CODE 4295070 4295071 4295072 DESCRIPTION LORAZEPAM 0.5MG TAB UD MAZICON 0.1MG ML 5ML VIAL MECLOFENAMATE 50MG CAP MEFOXIN 1GM VIAL MERCURY DISTILLED 1LB METAL ADD CAPS GLASS 25MM METHYLTESTOSTERONE 10MG METRONIDAZOLE 500MG TAB UD MONSELS SOLUTION 1PINT MULTIVITAMIN THERA TAB UD NAPHAZOLINE EYE DROPS 15ML NEUPOGEN 300MCG ML 1ML VL NIACIN 100MG TAB NICLOCIDE 500MG TAB NITROFURANTOIN 100MG CAP NITROSTAT 600MCG TAB SL100 CALCIUM OYSTER 500MG TAB PEDIAZOLE SUSPENSION 200ML PILOCARPINE 5% EYEDRP 15ML POTASSIUM IODIDE GRANULES PRELONE 15MG 5ML SYRUP 5ML PRINIVIL 10MG TAB UD PRINIVIL 5MG TAB UD PROCAINAMIDE 500MG CAP PROCAINE 1% NOVOCAINE ; 2ML PROPOXYPHENE-N 100 650TAB RABIES VACCINE SODIUM THIOSULFATE 2270GM SOTALOL 80MG TABLET SUFENTA 100MCG 2ML AMPULE SUFENTA 50MCG 1ML AMPULE SUPRAX 200MG TABLET SURGILUBE 4OZ TETRACAINE 0.5% EYE DROPS THERAPEUTIC MVI 5ML UD THERMO-TAB THIORIDAZINE 100MG ML LIQ TIMOLOL 10MG TAB UD TIMOPTIC 0.25% EYEDRP 5ML TORADOL 10MG TABLET UD TORADOL 15MG ML INJECTION TORADOL 30MG ML INJECTION TORADOL 60MG ML INJECTION TRANXENE 3.75MG TABLET TRIAMCINOLONE 4MG TABLET TRIMETHOBENZAMIDE 100MG SU VERSED 2MG 2ML INJECTION VITAMIN E 200IU CAPSULE DUODERM DRESSING 10CMX10CM KALTOSTAT 7.5CMX12CM KALTOSTAT 2GM DARVON COMPOUND TABLET PLASTIC ORAL SYRINGE 5 ML PREMARIN VAG CREAM 42GM HEP B VACC RENAL INJ GLYCOPYRROLATE 0.2MG ML 20ML MDV Page 68 of 230 PRICE 0.17 75.93 0.37 DEPARTMENT PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY PHARMACY and procrit.
Many of the provisions of the EPAct 2005 will have far reaching consequences for current and potential participants in the US energy industries. This is particularly so for persons who might be considering making investments in electric or natural gas utility assets or companies in the US or for persons who are considering participating in the newly emerging LNG trade in the US. As a general matter, the EPAct 2005 acts to eliminate or streamline barriers to investment and to encourage the importation of LNG into the US, although in each instance the regulatory authority of the FERC appears to be substantially expanded. Douglas Nordlinger & Benga Vecchio, Skadden Arps LLP.
Table 1. Observed and Calculated Values for Bodor's log P oct ; Dataseta logP oct ; name codeine flufenamic acid indomethacin methadone morphine phenylbutazone aprindine asocainol carocainide diltiazem disopyramide mexiletine moricizine nicainoprol procainamide propafenone quinidine sotalol verapamil chloramphenicol trimethoprim atropine phenytoin imipramine alizapride amisulpride sulpiride thiethylperazine cimetidine diphenhydramine chlorothiazide terazosin haloperidol acebutolol alprenolol and prohibit!
PHENYTOIN SODIUM Dilantin ; PICROTOXIN PIMOBENDEN Vetmedin ; PIROXICAM Feldene ; POTASSIUM BROMIDE K Br ; POTASSIUM CITRATE POTASSIUM G.S. GUAIACOL SULFONATE ; Resperese ; PREDNISOLONE PREDNISOLONE ACETATE PREDNISONE CIMETIDINE PREDNISONE PREDNISONE SUSPENSION for injection ; Meticorten ; PROCAINAMIDE HCL Pronestyl.
PGL3-Control containing SV40 promoter sequences; Promega ; , or with pGLGSTP1 prepared by cloning GSTP1 promoter sequences, GenBank positions 408 to 36, into pGL3-Basic; Promega ; in a manner described previously. The transfected cells were then treated for 24 h with and without procainamide and N-acetyl-procainamide in complete growth medium. To assess reporter gene expression, the transfected cells were lysed and then assayed for galactosidase activity using the -Galactosidase Enzyme Assay System with Reporter Lysis Buffer; Promega ; or for luciferase activity using the Luciferase Assay System with Reporter Lysis Buffer; Promega ; . To determine whether procainamide or N-acetyl-procainamide causes changes in histone acetylation, histone-containing protein extracts from LNCaP PCA cells that had been treated with the agents, or treated with the histone deacetylase inhibitor trichostatin A, were subjected to immunoblot analysis for histone acetylation, using rabbit antibodies specific for total H4 histone, for acetylated H4 histone, for acetyl-lysine 5 H4 histone, for acetyl-lysine 8 H4 histone, and for acetyllysine 12 H4 histone Serotec, Inc. ; . Total protein extracts, prepared by lysing the cells in buffer containing 2% SDS, were separated on a 10% polyacrylamide gel with 2- N-morpholino ; ethanesulfonic acid running buffer and then transferred to nitrocellulose membranes NOVEX; Invitrogen ; . The membranes were then probed with each of the rabbit anti-H4 histone antibodies, using antibody concentrations recommended by the manufacturer Serotec, Inc. ; . Rabbit anti-H4 histone antibody binding was detected using horseradish peroxidase-conjugated IgG Amersham ; and SuperSignal West Pico Chemiluminescent Substrate Pierce and prolixin.
Dispersion were performed by an ANOVA test. A regression analysis was used to assess the correlation between QTI, cQTI and ARI, and the correlation between the dispersion of these parameters. p 0.05 was considered to be statistically significant. Results Epicardial QTI, cQTI and ARI Bipolar ECG was obtained from an average of 18 3 epicardial sites. The average values of QTI, cQTI and ARI in the 10 animals were shown in Fig. 2. Procainamide infusion prolonged QTI, cQTI and ARI, but the increase in QTIs was not statistically significant p 0.07, Fig. 2 ; . Correlation between QTI, cQTI and ARI The correlation coefficients between QTI, cQTI and ARI in the 10 animals were shown in Table 1. No significant correlation was found in 9 of the 10 animals before or after procainamide infusion. In animal No. 8, however, there was a significant correlation between QTI, cQTI and ARI before procainamide administration p 0.01, Table 1 ; . Dispersions of QTI, cQTI and ARI The pooled QTI, cQTI and ARI dispersion in the 10 animals before and after procainamide administration were shown in Fig. 3. At baseline, cQTI dispersion was greater than QTI and ARI dispersion although this was not statistically significant.
As a result of exercise of the outstanding warrants, 56, 405 and 127, 419 additional shares of common stock were issued during the years ended February 28, 2002 and 2001, respectively. 2 ; Retirement of common stock In accordance with the resolution of the Board of Directors on February 24, 2000, the Company purchased 605 thousand shares of common stock out of profits for a total amount of 974 million from the stock market and retired them by the time of the 2000 annual meeting of shareholders held on May 25, 2000. 3 ; Stock split In accordance with the resolution of the Board of Directors on May 25, 2000, the Company authorized a stock split as follows: Effective date of stock split: August 21, 2000. Split ratio: Split one share of common stock into two shares. As a result of the stock split, 47, 523 thousand additional shares of common stock were issued and propantheline!
Red clover, burdock root, and Oregon grape root powders contain a number of different vitamin complexes and minerals plus other phytonutrients that synergistically help keep blood clean. The eliminative properties of red clover also support the lymphatic system in filtering toxins from the body.
Procainamide a lupus-like syndrome is most commonly seen with procainamide which, as noted above, may be mediated by the reactive metabolite procainamide hydroxylamine and propylthiouracil.
This suppression Table 2 ; . The increase in PRA produced by nitroprusside was enhanced by saralasin in both sodium-replete P 0.05 ; and -depleted P 0.001 ; dogs; captopril also increased the response in sodium-deprived dogs P 0.001 ; Table 2 ; . PRA did not change during saline infusion in either sodium-replete or -depleted dogs Table 2 ; . The AH results are summarized in Table 3. In general, changes in plasma AH paralleled the changes in PRA with two notable exceptions. First, plasma AH concentration Table 3 ; increased during AH infusion, whereas PRA was decreased Table 2 ; . Second, captopril treatment decreased plasma All concentration Table 3 ; and increased PRA Table 2 ; . Right and Left Atrial Pressures The effect of the different infusions on right atrial pressure is summarized in Table 4. Neither All infusion in sodium-replete dogs nor captopril or saralasin infusion in sodium-deprived dogs affected right atrial pressure Table 4 ; . In contrast, in each.
GENERIC PRODUCTS ARE ROUTINELY DISPENSED WHEN AVAILABLE NOTE: THIS FORMULARY IS SUBJECT TO CHANGE WITHOUT NOTIFICATION. WE RESERVE THE RIGHT TO LIMIT QUANTITIES Pharmacy Information: Hours: Monday Friday, 0730 1700 Except Holidays & designated Family days Typically, the 3rd Friday of each month is training day. Please call the refill line for hours of operation on that day. Call-in refills: 316 ; 759-6109 800 ; 643-2861 Pharmacy: 316 ; 759-5277 NEW REQUIREMENT: DoD Prior Authorization to be completed and accompanied with prescriptions for Lamisil tablets ADDITIONS: Amlodipine Norvasc ; 5, 10mg tab Imiquimod Aldara ; 5% cream Cefuroxime Ceftin ; 250, 500mg tab Celecoxib Celebrex ; 100, 200mg cap Desmopressin DDAVP ; 0.2mg tab Famotidine Pepcid ; 20mg tab Fluconazole Diflucan ; 10mg ml, 40mg ml Glipizide Extended-Release Glucotrol XL ; 5, 10mg tab Guaifenesin Codeine Robitussin AC ; 118ml Levalbuterol Xopenex ; 0.31mg 3ml, 0.63mg Levemir PENS 5x3ml ; Lidocaine Lidoderm ; 5% patch Metoprolol Succinate Toprol XL ; 25, 50, 100, tab Mirtazapine Remeron ; 15, 30, 45mg tab Novolog PENS 5x3ml ; Novofine 30 pen needles Pioglitazone Actos ; 15, 30, 45mg tab Tizanidine Zanaflex ; 4mg TABLETS DELETIONS: Acetyl Sulfixoxazole Gantrisin ; 500mg 5ml Belladona Phenobarbital Donnatal ; elixer Bisacodyl Dulcolax ; 10mg supp Cimetidine Tagament ; 400mg tab Colestipol Colestid ; 5gm tsp granules Cromolyn Intal ; 20mg 2ml nebs 60 vials ; Desmopressin DDAVP ; 100mcg nasal spray Fleet Prep-Kit #1 Fleet Phospho-Soda Oral 45ml btl Guaif Dextromethorphan Humibid DM ; tab Guaifenesin Pseudoephedrine ER Entex PSE ; 600 120mg tab Isoniazid INH ; 50mg 5ml syrup Magnesium Citrate solution, 10oz Mineral Oil Nedocromil Tilade ; 1.75mg, 104 inh Nitrofuantoin Fuadantin ; 25mg 5ml susp Procainamide SR Procan SR ; 500mg tab Psyllium w Dextrose Konsyl-D ; powder Simethicone Mylicon ; 40mg 0.6ml drops and protopic.
Order procainamide
Immunodeficient athymic nude mice with LNCaP PCA xenograft tumors were studied to determine whether the effect of procainamide on GSTP1 DNA hypermethylation could be reproduced in vivo. Following treatment of the mice with either procainamide or 5-aza-dC, the tumors were excised and stained with anti-GSTP1 antibody. Procainamide was found to be as effective as 5-aza-dC at restoring GSTP1 expression Figure 2 ; . A significant P 0.0001 ; increase in the proportion of cells expressing GSTP1 mRNA after treatment with procainamide or 5-aza-dC was seen. Bisulfite genome sequencing analysis was used to determine the level of GSTP1 DNA methylation, in both LNCaP PCA cells cultivated in vitro and as xenograft tumors in mice. Following treatment of the mice with procainamide or 5-aza-dC, there was a decrease in the level of GSTP1 DNA hypermethylation Figure 3 ; . This suggests that procainamide restores GSTP1 expression by inhibiting DNA methylases, which results in a decrease in hypermethylation of GSTP1 CpG islands. Additional studies will be needed to determine whether procainamide and 5-aza-dC differ in their ability to reactivate specific genes that have been silenced by CpG island hypermethylation.
The first step in evaluating a urine sample is documentation of the appearance and color. Urine specimens should be shaken to determine whether such substances as soap have been added to the urine. Excessive bubble formation that is long lasting can indicate an attempt to adulterate the specimen.13 Liquid drain cleaner, chlorine bleach, liquid soap, ammonia, hydrogen peroxide, lemon juice, and eyedrops have been used to manipulate the urine. Other commercial products containing glutaraldehyde, sodium or potassium nitrate, peroxide and peroxidase, and pyridinium chlorochromate PCC ; are being sold to falsify urine specimens.14 Tetrahydrocannabinol THC ; assays tend to be the and protriptyline and procainamide.
Disaccharide composition analysis of the CS chains. The CS chains 50 g ; were digested with chondroitinase ABC 20 mU ; in 100 mM Tris-HCl, pH 8.0, containing 30 mM NaOAc and 0.01% BSA at 37C for 5 h Oike et al. 1980 ; . The samp les were dried in a Speed-Vac, and , the digests corresponding to 1215 g of CS chains were analyzed by HPLC Waters, Milford, MA ; on a 4.6 x 250-mm amino bonded silica PA03 column YMC Inc., Milford, MA ; using a linear gradient of 16-530 nm NaH2PO4 at a flow rate of 1 ml min Sugahara et al. 1994.
Table 2. Drugs associated with DIIHA investigated at American Red Cross Blood Services, Los Angeles, in the last 26 yrs. 19782003 ; Drug cefotetan ceftriaxone piperacillin tazobactam clavulanate fludarabine penicillin probenecid rifampicin cefotaxime sulbactam ticarcillin mefloquine cefoxitin chlorpropamide nafcillin phenacetin procainamide erythromycin tolmetin oxaliplatin Total Number of patients 74 12 5 and provigil.
Quinidine- is commonly implicated in drug-induced diarrhea, although other antiarrhythmic agents, such as lidocaine xylocaine ; or procainamide pronestyl ; , can also cause diarrhea.
Figure 7 effect of procainamide on automaticity of a spontaneously beating purkinje fiber studied at 36-370 c.
Quinidine with changes in QRS duration. Heart J 80: 453, 1970 Josephson ME, Caracta AR, Ricciutti MA, Lau SH, Damato AN: Electrophysiologic properties of procainamide in man. J Cardiol 33: 596, 1974 Kessler KM, Lowenthal DT, Warner H: Quinidine elimination in patients with congestive heart failure or poor renal function. N Engl J Med 290: 706, 1974 Leahey EB, Reiffel JA, Drusin RE, Heissenbuttel RH, Lovejoy WP, Bigger JT: Interaction between quinidine and digoxin. JAMA 240: 533, 1978 Reynolds EW, Vander Ark CR: Quinidine syncope and the delayed repolarization syndromes. Mod Concepts Cardiovasc Dis 45: 117, 1976 Selzer A, Wray HW: Quinidine syncope: paroxysmal ventricular fibrillation occurring during treatment of chronic atrial fibrillation. Circulation 30: 17, 1964.
|
